25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
Title VII of the Civil Rights Act requires employers in the healthcare industry to provide a reasona...
Read More >
California is potentially setting the precedent on how “employees” will be defined in the future. ...
Read More >
U.S. Citizenship and Immigration Services (USCIS) has announced that on December 2, 2019, its premiu...
Read More >
The Seventh Circuit Court of Appeals recently ruled that the American with Disabilities Act (“ADA”...
Read More >
Last week, on November 7 at the American Bar Association’s annual labor and employment law conferen...
Read More >
Some remembrances upon the passing of influential former Fed Chair Paul Volcker, a force in American...
Read More >